India Globalization Capital, Inc. (NYSEAMERICAN: IGC) is making a run for the top in the market this morning, gaining well over 50% before the bell. The gains come after the company announced that the FDA has approved a study for a potential Alzheimer’s disease Treatment. Here’s what you need to know:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
IGC Stock Climbs on FDA Approval of Alzheimer’s Study
In the press release, India Globalization Capital said that the United States Food and Drug Administration has authorized the initiation of a Phase 1 clinical trial. The trial is centered around the company’s investigational cannabinoid formulation for the treatment of patients with mild to severe dementia due to Alzheimer’s disease.
Read more at Alpha Stock News!